Replies to post #134074 on OWC Pharmaceutical Research Corp (OWCP)

[madtrader2132]

tionships
59 --
Background
Dr. Stanley Hirsch, D.Phil., has been the Group Chief Executive Officer at FuturaGene plc, since August 17, 2007 and also serves as its President. Dr. Hirsch has been Chief Executive Officer of FuturaGene Limited since August 2007. Dr. Hirsch served as the Chief Executive Officer of CBD Technologies Ltd. since 1998. He served as President of CBD Technologies, Ltd. He served as an Executive Director of Foamix Pharmaceuticals Ltd. He joined CBD Technologies in March 1995. Dr. Hirsch has extensive executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States. Prior to CBD, he was responsible for business development for a privately held group of healthcare companies, where he was responsible for structuring and managing joint ventures, startup companies, technology licensing and new product acquisitions. Previously, Dr. Hirsch served as General Manager of two diagnostics development companies, including Portman Pharmaceutical Industries. He has been involved in the development of automated systems for plant tissue culture and is a Co-Inventor of patents in Plant Biotechnology and Micro Propagation Systems. Dr. Hirsch has served as an Advisor to Venture Capital Funds and as a strategy and business development Advisor to various companies in the field of drug development, tissue regeneration and diagnostics. He has filled various board of director, general management and business development positions in the pharmaceutical and genetic diagnostics fields. He has been the Chairman of Foamix Pharmaceuticals Ltd. since May 16, 2016. Dr. Hirsch serves as Chairman of the Board of Directors of the Registrant. He has been Chairman of OWC Pharmaceutical Research Corp. since July 24, 2017. He has been Executive Director of FuturaGene plc., August 17, 2007. He has been a Director of Foamix Pharmaceuticals Ltd. since February 2005. Dr. Hirsch's educational experience includes a D.Phil in Cell Biology and Immunology from Oxford University, UK in 1982, a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa in 1979, among other academic honors and awards from Oxford University and University of Capetown.
Collapse Detail

[money2013]

That was extremely well said.

[skyhawk66]

Very well said and explained. This is why OWCP volume is so low Daily. Longs will not release a single share at these very very low levels. Patience is key as the company gets everything in order. When it does, watch out, we will easily be a $7.00 to $20 dollar stock I no time.

[richclaire2020]

my remaining shares were bought at .31 many more will be bought while the ship will continue to sink by investors that think there is no chance this will go back to where it came from again no guarantees they can take the money and run at anytime this is the otc not amz@ your great leaders that are gone very well may not be any better then the FRAUDS that just left us. Wake up and smell the coffee I would not buy a share of this until it makes a run nor would anyone with investment intelligence